CMS Strategy

Work with specific pharmaceutical and manufacturing firms to develop much needed clinical treatments, to combat numerous modalities, as well as provide guidance with the patent and FDA process to approval.

Develop tools to better integrate data from numerous disparate sources for the purpose of forecasting ‘best in class’ treatment protocols.

Provide tools to support asset management programs with full integration to healthcare ERP’s, EMR’s, and Manufacturer Portals.

Work with key partners to facilitate a reduction of potential deadly infections in the hospital environment.

Support the bottom line initiatives and fiscal strategies, with emphasis on maximizing revenues, and reducing unnecessary expenses.

In American hospitals alone, the Centers for Disease Control (CDC) estimates that Hospital acquired infections (HAI) account for an estimated 1.7 million infections and 99,000 associated deaths each year.
http://patientcarelink.org/improving-patient-care/healthcare-acquired-infections-hais/

The estimated direct medical cost of HAIs is around $10 billion annually, not including cost-shifting to private payers. Including cost-shifting, HAIs may cost closer to between $35 billion and $45 billion for acute-care hospitals annually.

The total direct, indirect and nonmedical social costs of HAIs are estimated at around $96 billion to $147 billion annually, including loss of work, legal costs, etc.